Verification of type 2 diabetes mellitus preventing application of semaglutide oral preparation by Mendelian randomization method

Abstract

The invention relates to the technical field of medicines, in particular to a type 2 diabetes mellitus preventing application of a semaglutide oral preparation which can be used as a treatment medicine for type 2 diabetes mellitus. The research of the invention finds that when the semaglutide oral preparation is taken, the risk that healthy people suffer from type 2 diabetes mellitus can be obviously reduced by reducing in-vivo blood sugar and glycosylated blood sugar levels under the condition of ensuring cardiovascular safety. People carrying specific genetic variation are regarded as medication people taking the semaglutide oral preparation mainly through Mendelian randomization, and the disease risk ratio of a medication group to a non-medication group is calculated through a Cox proportional risk model. It is found through drawing a health probability curve chart that the probability of suffering from type 2 diabetes mellitus of people with extremely high risk of type 2 diabetes mellitus can be remarkably reduced by taking the semaglutide oral preparation. Therefore, a scheme of taking a GLP-1 receptor agonist semaglutide oral preparation by healthy people with high type 2 diabetes mellitus risk is provided for preventing type 2 diabetes mellitus.

Description

technical field [0001] The present application relates to the field of drug technology, the field of using Mendelian randomization method to observe the effect of drugs. Background technique [0002] Diabetes is a global epidemic and is gradually becoming a disease that seriously threatens human health. At present, the number of people with diabetes worldwide is increasing year by year. According to the first "Global Diabetes Report" released by WHO, in 2014, 422 million people (or 8.5% of the population) suffered from diabetes worldwide, mainly in developing countries. . In 2012, diabetes was directly responsible for 1.5 million deaths and an estimated 2.2 million indirectly. Diabetes is predicted to be the seventh leading cause of death worldwide by 2030. my country currently adopts the WHO (1999) diabetes etiology classification system, which is divided into 4 categories, namely type 1 diabetes, type 2 diabetes, special type diabetes and gestational diabetes, of which ...

AI Technical Summary

Problems solved by technology

Type 2 diabetes is a progressive disease in which the patient's condition deteriorates over time and it is difficult to control blood sugar well in the long term even with conventional medication

However, if this experimental method is applied to explore whether semaglutide can prevent diabetes in non-diabetic patients, it will cause a series of medical ethics issues, mainly including unknown side effects that may cause unpredictable and difficult treatment for the subjects. Adverse reactions, such as gastrointestinal adverse reactions, renal dysfunction, etc. [Zhu Yi, Feng Yufei. Pharmacological and clinical evaluation of GLP-1 receptor agonist semaglutide [J]. Clinical Drug Zhizhi, 2018, 16(03):17-21+27]

In addition, carrying out large-sample RCT requires a lot of manpower, financial support, and long-term investment, and researchers will face many difficulties in conducting a high-quality randomized controlled trial; one of its limitations is that randomized controlled trial population extrapolation is often limited one

From a scientific point of view, randomized controlled trials select a certain sample of specific groups of people through a series of inclusion and exclusion criteria, so it is impossible to determine the generalizability in real clinical practice. In addition, due to the design of control variables, randomized controlled trials seldom obtain relevant information. Concomitant disease and concomitant treatment information, and often more interventions to comply with the study protocol, which is not realistic in clinical practice

Images